AIM: To investigate the effectiveness and toxicity of radiotherapy (RT) given as 17 Gy in 2 fractions, in patients with locally advanced non-small-cell lung cancer (NSCLC) previously treated by platinum-based chemotherapy (CHT) and the impact of total tumor volume (TTV) on symptoms control. MATERIALS AND METHODS: Patients with inoperable NSCLC resistant to induction platinum-based CHT, who developed symptoms during or just after radiotherapy, were treated by 17 Gy in two fractions one week apart. In 12/28 patients a minimal response (up to 20% of TTV) and in 16/28 a stable or locally progressive disease had been recorded after induction CHT. In 26/28 patients, symptoms were present during-after CHT and before RT. The prognostic significance of pre-RT TTV on symptoms control and patients survival was also examined. RESULTS: We report on 28 patients. Response rates for the four main symptoms were: cough 13/19 (68%), haemoptysis 9/10 (90%), pain 8/14 (57%) and dyspnoea 5/13 (38%). Hematologic and local-thoracic toxicities were minimal. The median survival from the beginning of RT, for the whole group of patients was 9 months (95% CI:3.7-14.3), while for those patients with TTV<120 cc it was 12 months, and for those with TTV 120cc, it was 5.2 months. TTV was not suggested to influence symptoms control rate. CONCLUSION: The two-fraction radiotherapy course is safe and effective in palliation of symptomatic non-small-cell lung cancer patients non-responding to induction CHT. Present data suggests that the TTV may influence survival time.
AIM: To investigate the effectiveness and toxicity of radiotherapy (RT) given as 17 Gy in 2 fractions, in patients with locally advanced non-small-cell lung cancer (NSCLC) previously treated by platinum-based chemotherapy (CHT) and the impact of total tumor volume (TTV) on symptoms control. MATERIALS AND METHODS:Patients with inoperable NSCLC resistant to induction platinum-based CHT, who developed symptoms during or just after radiotherapy, were treated by 17 Gy in two fractions one week apart. In 12/28 patients a minimal response (up to 20% of TTV) and in 16/28 a stable or locally progressive disease had been recorded after induction CHT. In 26/28 patients, symptoms were present during-after CHT and before RT. The prognostic significance of pre-RT TTV on symptoms control and patients survival was also examined. RESULTS: We report on 28 patients. Response rates for the four main symptoms were: cough 13/19 (68%), haemoptysis 9/10 (90%), pain 8/14 (57%) and dyspnoea 5/13 (38%). Hematologic and local-thoracic toxicities were minimal. The median survival from the beginning of RT, for the whole group of patients was 9 months (95% CI:3.7-14.3), while for those patients with TTV<120 cc it was 12 months, and for those with TTV 120cc, it was 5.2 months. TTV was not suggested to influence symptoms control rate. CONCLUSION: The two-fraction radiotherapy course is safe and effective in palliation of symptomatic non-small-cell lung cancerpatients non-responding to induction CHT. Present data suggests that the TTV may influence survival time.
Entities:
Keywords:
Non-small-cell lung cancer; and fractionation; chemotherapy; palliation; radiotherapy
Authors: Andrea Bezjak; Peter Dixon; Michael Brundage; Dong Tu; Michael J Palmer; Paul Blood; Clive Grafton; Catherine Lochrin; Carson Leong; Liam Mulroy; Colum Smith; James Wright; Joseph L Pater Journal: Int J Radiat Oncol Biol Phys Date: 2002-11-01 Impact factor: 7.038
Authors: U Nestle; C Nieder; K Walter; U Abel; D Ukena; G W Sybrecht; K Schnabel Journal: Int J Radiat Oncol Biol Phys Date: 2000-08-01 Impact factor: 7.038
Authors: Chaundré K Cross; Stuart Berman; Lori Buswell; Bruce Johnson; Elizabeth H Baldini Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038
Authors: T S Lewis; J A Kennedy; G J Price; T Mee; D K Woolf; N A Bayman; C Chan; J H Coote; C Faivre-Finn; M A Harris; A M Hudson; L S Pemberton; A Salem; H Y Sheikh; H B Mistry; D C P Cobben Journal: Clin Oncol (R Coll Radiol) Date: 2020-06-26 Impact factor: 4.126